Meridian Bioscience Inc
NASDAQ:VIVO
Meridian Bioscience Inc
NASDAQ:VIVO
Price:
33.97 USD
Market Closed
Updated:
May 11, 2024
P/S
Price to Sales
Price to Sales
4.5
Current
3.5
Median
2.4
Industry
Higher
than median
Higher
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=4.5
Market Cap
/
1.5B
Revenue
333m
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| US |
|
Meridian Bioscience Inc
NASDAQ:VIVO
|
1.5B USD | 4.5 | |
| JP |
|
Hoya Corp
TSE:7741
|
6.3T JPY | 8.4 | |
| CH |
|
Alcon AG
SIX:ALC
|
36.3B CHF | 4.2 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
190B DKK | 7.6 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
20.4B USD | 5.2 | |
| US |
|
Cooper Companies Inc
NYSE:COO
|
18.8B USD | 5.1 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
13.1T KRW | 305.8 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
61.2B CNY | 15 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
5.4B GBP | 3.1 | |
| US |
|
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
5.8B USD | 1.5 | |
| CA |
B
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.4B USD | 1.3 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
5.1
2-Years Forward
P/S
N/A
3-Years Forward
P/S
N/A
You don't have any saved screeners yet
